Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (6): 1153-1156. doi: 10.19723/j.issn.1671-167X.2020.06.029

Previous Articles     Next Articles

  

  • Received:2018-08-10 Online:2020-12-18 Published:2020-12-13
  • Supported by:
    First Hospital of Lanzhou University Foundation(ldyyyn2014-14)

RICH HTML

   

PDF (PC)

CLC Number: 

  • R512.6

Table 1

Immune function in ALT normal type B and type C genotypes chronic hepatitis B patients (n= 124)"

Genotype n HBV DNA/
(lg copies/mL)		 T lymphocyte
(CD3+)/%		 Th/i
(CD3+
CD4+)/%		 Ti/c
(CD3+
CD8+)/%		 Th/c
(CD4+
CD8+)/%		 IL-2/
(ng/L)		 IFN-γ/
(ng/L)		 IL-4/
(ng/L)		 IL-10/
(ng/L)
B type 61 5.25±1.84 63.87±10.12 43.16±7.11 28.66±6.09 1.46±0.68 37.83±18.55 9.72±2.76 42.82±20.75 15.18±5.87
C type 63 5.29±1.73 64.23±9.98 43.98±8.24 28.99±6.73 1.49±0.72 38.41±19.68 10.75±3.12 43.29±21.75 16.21±5.92
t 0.553 0.311 0.658 0.574 0.548 0.421 0.541 0.387 0.753
P 0.621 0.728 0.496 0.602 0.617 0.684 0.595 0.709 0.417

Table 2

Immune function in ALT greater than or equal to the upper limit of normal, and less than 2 times higher than the upper limit of normal type B and type C genotypes chronic hepatitis B patients (n= 127)"

Genotype n HBV DNA/
(lg copies/mL)		 T lymphocyte
(CD3+)/%		 Th/i
(CD3+
CD4+)/%		 Ti/c
(CD3+
CD8+)/%		 Th/c
(CD4+
CD8+)/%		 IL-2/
(ng/L)		 IFN-γ/
(ng/L)		 IL-4/
(ng/L)		 IL-10/
(ng/L)
B type 65 5.38±1.39 59.36±12.32 41.86±7.65 31.85±6.75 1.30±0.73 43.89±21.73 14.73±9.07 42.95±18.93 16.84±6.87
C type 62 5.55±1.42 58.96±13.67 40.18±7.63 32.76±6.39 1.25±0.63 54.61±23.85 20.46±11.58 39.51±17.48 15.73±7.39
t 0.390 0.768 0.775 0.511 0.861 1.904 2.058 0.275 0.287
P 0.699 0.403 0.398 0.629 0.265 0.038 0.027 0.784 0.793

Table 3

Immune function in ALT greater than or equal to 2 times higher than the upper limit of normal type B and type C genotypes chronic hepatitis B patients (n= 124)"

Genotype n HBV DNA/
(lg copies/mL)		 T lymphocyte
(CD3+)/%		 Th/i
(CD3+
CD4+)/%		 Ti/c
(CD3+
CD8+)/%		 Th/c
(CD4+
CD8+)/%		 IL-2/
(ng/L)		 IFN-γ/
(ng/L)		 IL-4/
(ng/L)		 IL-10/
(ng/L)
B type 63 5.85±1.38 55.63±11.17 37.35±6.83 34.63±6.72 1.07±0.74 61.73±27.74 29.76±15.43 40.84±21.06 15.32±7.92
C type 61 5.76±1.64 51.84±10.03 33.68±6.95 38.17±6.29 0.86±0.52 83.92±31.84 42.63±25.73 36.84±23.97 10.96±8.04
t 0.775 1.957 3.876 4.002 4.785 2.953 3.748 1.818 1.723
P 0.485 0.038 0.000 0.000 0.000 0.000 0.000 0.016 0.032
[1] 中华医学会传染病学会肝病分会. 病毒性肝炎防治方案[J]. 中华肝脏病杂志, 2010,12(6):324-326.
[2] Lin CL, Kao JH. Hepatitis B virus genotypes: Clinical relevance and therapeutic implications[J]. Curr Hepat Rep, 2013,12(2):124-132.
doi: 10.1007/s11901-013-0166-6
[3] Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances[J]. J Gastroenterol Hepatol, 2011,26(Suppl 1):123-130.
[4] Busch K, Thimme R. Natural history of chronic hepatitis B virus infection[J]. Med Microbiol Immunol, 2015,204(1):5-10.
pmid: 25540037
[5] Burns GS, Thompson AJ. Viral hepatitis B: Clinical and epidemiological characteristics[J]. Cold Spring Harb Perspect Med, 2014,4(12):1101-1112.
[6] Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship[J]. World J Gastroenterol, 2014,20(30):10395-10404.
doi: 10.3748/wjg.v20.i30.10395 pmid: 25132755
[7] Kandilarova SM, Georgieva AI. Immune cell subsets evaluation as a predictive tool for hepatitis B infection outcome and treatment responsiveness[J]. Folia Med, 2017,59(1):53-62.
[8] Lok AS, Zoulim F. Hepatitis B cure: From discovery to regulatory approval[J]. J Hepatol, 2017,66(4):847-861.
[9] Bertoletti A, Ferrari C. Adaptive immunity in HBV infection[J]. J Hepatol, 2016,64(Suppl 1):71-77.
[10] Park JJ, Wong DK. Hepatitis B virus: specific and global T-cell dysfunction in chronic hepatitis B[J]. Gastroenterology, 2016,150(3):684-695.
doi: 10.1053/j.gastro.2015.11.050 pmid: 26684441
[11] Liu Y, Cheng LS. IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection[J]. Clin Sci (Lond), 2016,130(11):907-919.
doi: 10.1042/CS20160069
[12] Dinney CM, Zhao LD. Regulation of HBV-specific CD8(+) T cell-mediated inflammation is diversified in different clinical presentations of HBV infection[J]. J Microbiol, 2015,53(10):718-724.
doi: 10.1007/s12275-015-5314-y pmid: 26428923
[1] GAO Peng,LUO Yan-ping,LI Jun-feng,CHEN lin,MAO Xiao-rong. Effects of hepatitis B virus on Th17, Treg and Th17/Treg ratio in different alanine aminetransferase stages [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 272-277.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd